Literature DB >> 9669387

Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis.

Y Yamada1, Y Uchida, K Tatsumi, T Yamaguchi, H Kimura, H Kitahara, T Kuriyama.   

Abstract

UNLABELLED: Uptake of 18F-fluorodeoxyglucose (FDG) and 11C-methionine (Met) in mediastinum and hilar lymph nodes was studied using PET in 31 patients with sarcoidosis. The aim of our study was to examine whether these different tracers play a differential role in clinical assessment of pulmonary involvement.
METHODS: Fluorine-18-fluorodeoxyglucose and 11C-Met PET were administered on different days. The differential absorption ratio of these tracers was calculated for the region of interest with the highest level of activity. Clinical reassessment of sarcoidosis was made at least 1 yr after the first PET examination. In seven patients whose lymph nodes still remained visible by other imagings at the time of reevaluation, the same PET study was performed again.
RESULTS: Both FDG and Met were accumulated in the lymph nodes in all but one patient. The FDG and Met uptake ratios in all patients were not correlated, but they could be divided into the FDG-dominant group (FDG/Met uptake ratio > or = 2) and the Met-dominant group (FDG/Met uptake ratio < 2). Within each group, the FDG and Met uptake values were correlated. The rate of improvement assessed by clinical status and chest radiographs was considerably higher in the FDG- (78%) than in the Met-dominant group (33%). In the seven patients of the repeated PET examination, their FDG/Met uptake ratios were generally unchanged after 1 yr.
CONCLUSION: The results suggest that the FDG/Met uptake ratio using PET may reflect the differential granulomatous status in sarcoidosis and be a useful tool for pretreatment evaluation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9669387

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  20 in total

1.  FDG-PET for preoperative differential diagnosis between benign and malignant soft tissue masses.

Authors:  J Aoki; H Watanabe; T Shinozaki; K Takagishi; M Tokunaga; Y Koyama; N Sato; K Endo
Journal:  Skeletal Radiol       Date:  2003-01-24       Impact factor: 2.199

2.  (18)F-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis.

Authors:  Ruth G Keijsers; Jan C Grutters; Heleen van Velzen-Blad; Jules M van den Bosch; Wim J Oyen; Fred J Verzijlbergen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-16       Impact factor: 9.236

3.  Dynamic 11C-methionine PET analysis has an additional value for differentiating malignant tumors from granulomas: an experimental study using small animal PET.

Authors:  Songji Zhao; Yuji Kuge; Min Yi; Yan Zhao; Toshiyuki Hatano; Keiichi Magota; Ken-ichi Nishijima; Masashi Kohanawa; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-06       Impact factor: 9.236

4.  Diagnostic usefulness of an amino acid tracer, α-[N-methyl-(11)C]-methylaminoisobutyric acid ( (11)C-MeAIB), in the PET diagnosis of chest malignancies.

Authors:  Ryuichi Nishii; Tatsuya Higashi; Shinya Kagawa; Yoshihiko Kishibe; Masaaki Takahashi; Hiroshi Yamauchi; Hideki Motoyama; Kenzo Kawakami; Takashi Nakaoku; Jun Nohara; Misato Okamura; Toshiki Watanabe; Koichi Nakatani; Shigeki Nagamachi; Shozo Tamura; Keiichi Kawai; Masato Kobayashi
Journal:  Ann Nucl Med       Date:  2013-07-04       Impact factor: 2.668

5.  18F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with 18F-FDG and 11C-Methionine PET.

Authors:  Tadashi Watabe; Hayato Ikeda; Shushi Nagamori; Pattama Wiriyasermkul; Yoko Tanaka; Sadahiro Naka; Yasukazu Kanai; Kohei Hagiwara; Masanao Aoki; Eku Shimosegawa; Yoshikatsu Kanai; Jun Hatazawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-22       Impact factor: 9.236

6.  Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas.

Authors:  Elena Karavaeva; Robert J Harris; Kevin Leu; Maryam Shabihkhani; William H Yong; Whitney B Pope; Albert Lai; Phioanh L Nghiemphu; Linda M Liau; Wei Chen; Johannes Czernin; Timothy F Cloughesy; Benjamin M Ellingson
Journal:  Mol Imaging Biol       Date:  2015-06       Impact factor: 3.488

7.  False positive accumulation in 18F fluorodeoxyglucose positron emission tomography scan due to sarcoid reaction following induction chemotherapy for lung cancer.

Authors:  Jun Maeda; Mitsunori Ohta; Hirohisa Hirabayashi; Hikaru Matsuda
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-04

8.  Pilot study of the utility of the synthetic PET amino-acid radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions.

Authors:  Rianot Amzat; Pooneh Taleghani; Daniel L Miller; Jonathan J Beitler; Leah M Bellamy; Jonathon A Nye; Weiping Yu; Bital Savir-Baruch; Adeboye O Osunkoya; Zhengjia Chen; William F Auffermann; Mark M Goodman; David M Schuster
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

9.  Differentiation of mediastinal FDG uptake observed in patients with non-thoracic tumours.

Authors:  Won Jun Kang; June-Key Chung; Young So; Jae Min Jeong; Dong Soo Lee; Myung Chul Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

10.  18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis.

Authors:  Ruth G Keijsers; Fred J Verzijlbergen; Wim J Oyen; Jules M van den Bosch; Henk J Ruven; Heleen van Velzen-Blad; Jan C Grutters
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-04       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.